Cagrilintide
Long-acting amylin analog in Phase III clinical development. Studied for obesity management, particularly in the CagriSema combination with sema. Slow titration required for GI tolerability.
Cagrilintide is a long-acting synthetic amylin analog developed by Novo Nordisk for obesity management. Amylin is a peptide hormone co-secreted with insulin that regulates satiety, gastric emptying, and GCG secretion. Cagrilintide is designed for once-weekly subcutaneous dosing.
The rationale for combining amylin agonism with GLP-1 agonism is mechanistic complementarity. The CagriSema combination (cagrilintide + sema) is in Phase III development and has shown promising preliminary data suggesting enhanced outcomes versus either agent alone.
Physician practice use involves slow titration from 0.1 mg weekly up to 1–1.5 mg weekly over months. The cumulative GI burden of combining amylin agonism with GLP-class agents requires careful assessment and ongoing monitoring.
What are you researching?
Tell us your focus area and we’ll send a personalized research guide.
Cagrilintide is not approved for any indication. GI adverse effects are the primary concern, especially in combination with GLP agents. WADA-prohibited. Research use only. All information for educational reference only.